Vericel Corp  

(Public, NASDAQ:VCEL)   Watch this stock  
Find more results for NASDAQ:ASTM
+0.11 (5.12%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.15 - 2.43
52 week 1.69 - 6.69
Open 2.17
Vol / Avg. 289,399.00/116,863.00
Mkt cap 54.09M
P/E     -
Div/yield     -
EPS -0.94
Shares 23.93M
Beta 2.36
Inst. own 55%
Aug 10, 2016
Q2 2016 Vericel Corp Earnings Release (Estimated) Add to calendar
Jul 12, 2016
Vericel Corp at Cantor Fitzgerald Healthcare Conference
May 10, 2016
Q1 2016 Vericel Corp Earnings Call
May 10, 2016
Q1 2016 Vericel Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -25.87% -31.93%
Operating margin -14.12% -32.58%
EBITD margin - -29.45%
Return on average assets -43.46% -39.91%
Return on average equity - -
Employees 190 -
CDP Score - -


64 Sidney St
CAMBRIDGE, MA 02139-4170
United States - Map
+1-734-9305555 (Phone)
+1-734-6650485 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Officers and directors

Robert L. Zerbe M.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Dominick C. Colangelo President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Gerard J. Michel Chief Financial Officer, Vice President - Corporate Development
Age: 51
Bio & Compensation  - Reuters
Daniel R. Orlando Chief Operating Officer, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Ross Tubo Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
David Recker M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Steven C. Gilman Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Heidi Hagen Director
Age: 46
Bio & Compensation  - Reuters
Kevin F. McLaughlin Director
Age: 58
Bio & Compensation  - Reuters
Paul K. Wotton Ph.D. Director
Age: 55
Bio & Compensation  - Reuters